Scinai posts net income on $6.2M acquisition bargain gain
Scinai Immunotherapeutics (NASDAQ:SCNI) reported a net profit for the first quarter of fiscal year 2026, driven primarily by a substantial, non-cash accounting gain linked to its recent acquisition of Recipharm Israel.










